Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4297730

CONCIZUMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available

Basic Information

ChEMBL ID CHEMBL4297730
Name CONCIZUMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Alhemo Anti-TFPI Concizumab Concizumab-mtci MAB-2021 mAb2021 NN-7415 NN7415 NNC 0172-0000-2021 NNC-0172-0000-2021 NNC0172-2021 NNC01722021 +1 more
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
13
Known Names
3
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2024
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral
USAN Stem -mab; -mab
USAN Year 2020

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Tissue factor pathway inhibitor inhibitor INHIBITOR Tissue factor pathway inhibitor

Indications

Hemorrhage Hemophilia A Hemophilia B

ATC Classification

B02BX10
concizumab
Level 1: BLOOD AND BLOOD FORMING ORGANS
Level 2: ANTIHEMORRHAGICS

Data from ChEMBL 36 via Core Engine